독성 시험 아웃소싱 시장 규모, 점유율, 동향 분석 보고서 : 방법별, GLP별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Toxicity Testing Outsourcing Market Growth & Trends:

The global toxicity testing outsourcing market size is expected to reach USD 6.36 billion by 2030, registering a CAGR of 9.52% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing attrition rate in preclinical studies is stimulating demand for the outsourcing of preclinical studies to the CROs, which offer end-to-end services including toxicology testing services. Also, rising growth and innovation in pharmaceutical and biopharmaceutical companies, augment in R&D, and increasing ethical concerns about animal use are driving the enlargement of the market.

COVID-19 has significantly impacted the market for toxicity testing outsourcing. During the crisis, vaccine, medical device, and biologic contract research and manufacturing service providers played a predominant role in meeting the needs of pharmaceutical companies, biotech companies, and other end users. These organizations have been actively working towards the development of healthcare products that can be used as a treatment for patients, suffering from COVID-19 with mild symptoms, since the end of 2019. And these products require toxicity testing at each stage to assess safety and effectiveness, thus contributing to market growth.

Companies in the pharmaceutical and biopharmaceutical industries operate in an environment that is becoming more complex to understand. Improvements in many therapeutic areas, as well as the emergence of new types of therapies such as genetically targeted therapies, biologics, stem cell therapies, and other treatment modalities, have resulted in more complex development and regulatory pathways. To develop a treatment that is secure and efficient, it is necessary to do toxicity testing at each stage, which is boosting the market's growth.

Toxicity Testing Outsourcing Market Report Highlights:

• In 2024, the in vitro segment dominated the market, accounting for a revenue share of 57.97%. This growth is anticipated to be fueled by several factors, including increased product development activities, rising R&D spending, growing toxicological awareness, and an increasing preclinical pipeline.
• GLP segment accounted for the larger market share in 2024. Clinical studies, including safety pharmacology, genotoxicity, and repeated toxicity, are mandatory for safe exposure to humans and must be performed as per the standards of GLP.
• In 2024, the pharmaceutical and biopharmaceutical companies segment dominated the market, accounting for a revenue share of 61.41%.
• North America toxicity testing outsourcing market dominated the global market in 2024 with the largest share of 43.13%. This can be attributed to the growth of the pharmaceutical industries in the U.S. and Canada.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis
  • 1.6.2. Bottom-up Approach
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Toxicity Testing Outsourcing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growth and innovation in the life sciences industry
    • 3.2.1.2. Increased investment in research and development
    • 3.2.1.3. Increasing Complexity in Research and Development
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Monitoring issues and lack of standardization
• 3.3. Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Toxicity Testing Outsourcing Market: Method Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Toxicity Testing Outsourcing Market; Method Movement Analysis
• 4.3. Global Toxicity Testing Outsourcing Size & Trend Analysis, by Method, 2018 to 2030 (USD Million)
• 4.4. In vitro
  • 4.4.1. In vitro market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. In vivo
  • 4.5.1. In vivo market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Toxicity Testing Outsourcing Market: Glp Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Toxicity Testing Outsourcing Market; Glp Movement Analysis
• 5.3. Global Toxicity Testing Outsourcing Size & Trend Analysis, by Glp, 2018 to 2030 (USD Million)
• 5.4. GLP
  • 5.4.1. GLP market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Non GLP
  • 5.5.1. Non GLP market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Toxicity Testing Outsourcing Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Toxicity Testing Outsourcing Market; End Use Movement Analysis
• 6.3. Global Toxicity Testing Outsourcing Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Pharmaceutical and Biopharmaceutical Companies
  • 6.4.1. Pharmaceutical and biopharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Academic and Research Institutes
  • 6.5.1. Academic and research institutes market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Toxicity Testing Outsourcing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. North America
  • 7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Competitive scenario
    • 7.3.2.3. Regulatory framework
    • 7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Competitive scenario
    • 7.3.3.3. Regulatory framework
    • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Competitive scenario
    • 7.3.4.3. Regulatory framework
    • 7.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Competitive scenario
    • 7.4.5.3. Regulatory framework
    • 7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Competitive scenario
    • 7.4.6.3. Regulatory framework
    • 7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Competitive scenario
    • 7.4.7.3. Regulatory framework
    • 7.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Competitive scenario
    • 7.4.8.3. Regulatory framework
    • 7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Competitive scenario
    • 7.4.9.3. Regulatory framework
    • 7.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Company Market Position Analysis, 2023
• 8.3. Company Profiles
  • 8.3.1. Eurofins Scientific
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Service benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. SGS SA
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Service benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Charles River Laboratories
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Service benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Thermo Fisher Scientific, Inc
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Service benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Intertek Group plc
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Service benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Catalent, Inc
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Service benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. ICON plc
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Service benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Med pace
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Service benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Wuxi AppTec
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Service benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Labcorp Drug Development
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Service benchmarking
    • 8.3.10.4. Strategic initiatives